Open Orphan PLC operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Open Orphan PLC with three other
companies in this sector in UNITED KINGDOM :
Fusion Antibodies PLC
sales of £2.18 million [US$3.00 million]
Redx Pharma PLC
(£3.13 million [US$4.30 million]
of which 100%
was pharmaceutical), and
Avacta Group Plc
(£3.89 million [US$5.34 million]
of which 60%
was Life Sciences).
Sales fell dramatically in 2019:
During the year ended December of 2019, sales at
Open Orphan PLC were £3.84 million (US$5.28 million).
decrease of 68.8%
versus 2018, when the company's sales were £12.33 million.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Open Orphan PLC had sales
of £3.92 million.